sabato, 5 dicembre 2020
Medinews
28 Agosto 2018

FDA Grants Fast Track Designation to AVB-S6-500 for Platinum-Resistant Ovarian Cancer

August 23, 2018 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer. AVB-S6-500 is a novel high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Research has shown GAS6-AXL signaling to be a key molecular pathway that promotes … (leggi tutto)

TORNA INDIETRO